Korsana Biosciences Inc. (KRSA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Korsana Biosciences Inc. (KRSA) advanced +0.37% to $30.22, trading at 44% of its 52-week range ($7.19 – $59.36). Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KRSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KRSA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Korsana Biosciences Inc. (KRSA) ranks #859 by composite RQD confidence (33/100, grade E) and #315 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, KRSA leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with KRSA at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRSA
ACTIVE
Korsana Biosciences Inc. | E | 33/100 | — | — | -5.7% | +0.37% | $1.38B | Benchmark Subject |
| OMER Omeros Corporation | D | 46/100 | — | — | -35.0% | +5.98% | $1.37B | /omer-vs-krsa → |
| AAPG Ascentage Pharma Group International American Depository Shares | D+ | 57/100 | — | — | — | -0.70% | $1.39B | /aapg-vs-krsa → |
| DMRA Damora Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.85% | $1.36B | /dmra-vs-krsa → |
| KARD Kardigan Inc. | C- | 61/100 | — | — | — | +4.22% | $1.34B | /kard-vs-krsa → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Korsana Biosciences Inc. (KRSA) reported GAAP revenue of $2.1M (+3.7% vs. FY2024 revenue of $2.0M ) , GAAP net income of -$3.5M, operating cash flow of -$3.3M, and free cash flow of -$3.3M (+23.5% YoY). On the balance sheet, KRSA closed FY2025 with $10.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.1M | -$3.5M | -$3.3M | -$3.3M | $10.0M | — |
| FY2024 (FY) | 2024-12-31 | $2.0M | -$3.1M | -$4.3M | -$4.3M | $9.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$5.3M | -$21.2M | -$21.2M | — | — |
As of 2026-11-01, Korsana Biosciences Inc. (NASDAQ: KRSA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $30.22 (+0.37% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KRSA ranks #859 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRSA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.7%. By comparison, OMER (Omeros Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B) and AAPG (Ascentage Pharma Group International American Depository Shares) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $1.39B). Among the 5-stock peer group, KRSA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).
Per KRSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001755237), Korsana Biosciences Inc. generated $2.1M in revenue (+3.7% YoY), -$3.5M in net income, and -$3.3M in free cash flow against $10.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KRSA last traded at $30.22 (+0.37% on volume of 138,999 shares), positioning the stock -2.80% below its 50-day simple moving average ($31.09) and +37.68% above its 200-day simple moving average ($21.95). Across its 52-week range of $7.19 to $59.36, KRSA sits at the 44.1% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($26.44 to $34.00).
Why KRSA Stock advanced +0.37% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-6% return on capital) under elevated 10-year interest-rate pressure.